Ferran Prat Escude

Ferran Prat Escude currently serves as Chief Commercial Officer at BostonGene since April 2025 and is a Board Member for CTMC, a joint venture between MD Anderson Cancer Center and Resilience National since August 2022. Previously, Ferran held significant roles at MD Anderson Cancer Center from March 2013 to April 2025, including Senior VP of Research Administration & Industry Relations and VP of Strategic Industry Ventures. Additionally, Ferran served on the Board of Directors for Syena Inc. from February 2023 to March 2025 and Vescor from May 2018 to April 2023. Educational accomplishments include a J.D. from the University of San Diego School of Law and a Ph.D. in Chemistry from UCLA.